论文部分内容阅读
目的 :探讨P 糖蛋白免疫组化检测与肿瘤多药耐药相关性及评价其与并用耐药逆转剂化疗的临床疗效。方法 :92例癌症患者经P 糖蛋白免疫组化检测分为阳性组 (P组 )和阴性组 (N组 ) ,在P组中随机抽取 2 3例 (P1组 )给予化疗并用三苯氧胺 (TAM)和 (或 )异博定 (VPL) ,P组中余 2 1例 (P2组 )和N组 4 8例仅给予化疗。按原发灶、淋巴结转移和脏器转移灶分别计算并判定总疗效 (CR +PR)并比较毒性作用。结果 :有效率 (CR +PR) %在P1组为 6 0 % ;P2组为 34% ;N组为 5 8% ;N组有效率显著高于P2组 (P <0 0 5 ) ,P1组有效率显著高于P2组 (P <0 0 5 )。化疗并用TAM和 (或 )VPL的毒性比较进行统计无明显差别 (χ2 =0 0 10 2 )。结论 :P 糖蛋白的免疫组化检测高表达与肿瘤耐药相关且阳性者并用VPL及TAM化疗可明显提高疗效 ,无明显毒性增强作用
Objective: To investigate the correlation between P-glycoprotein immunohistochemistry and multidrug resistance in tumor and to evaluate its clinical efficacy in combination with drug resistance reversal agents. Methods: Ninety-two cancer patients were divided into positive group (P group) and negative group (N group) by P-glycoprotein immunohistochemistry. Twenty-three patients in group P were randomly assigned to receive chemotherapy with tamoxifen (TAM) And (or) Volapirin (VPL), more than 21 patients in group P (group P2) and 48 patients in group N received chemotherapy only. According to the primary tumor, lymph node metastasis and organ metastases were calculated and determine the total effect (CR + PR) and more toxic effects. Results: The effective rate (CR + PR)% was 60% in group P1, 34% in group P2 and 58% in group N, and the effective rate in group N was significantly higher than that in group P2 (P <0.05) The effective rate was significantly higher than P2 group (P <0 05). Chemotherapy and TAM and / or VPL toxicity comparison statistically no significant difference (χ2 = 0 0 10 2). Conclusion: Immunohistochemical detection of P-glycoprotein with high expression correlated with tumor drug resistance and positive with VPL and TAM chemotherapy can significantly improve the efficacy without significant toxicity enhancement